Identification of robust reference genes for studies of gene expression in FFPE melanoma samples and melanoma cell lines

Julie N. Christensen\textsuperscript{a}, Henrik Schmidt\textsuperscript{b}, Torben Steiniche\textsuperscript{c} and Mette Madsen\textsuperscript{a}

There is an urgent need for novel diagnostic melanoma biomarkers that can predict increased risk of metastasis at an early stage. Relative quantification of gene expression is the preferred method for quantitative validation of potential biomarkers. However, this approach relies on robust tissue-specific reference genes. In the melanoma field, this has been an obstacle due to lack of validated reference genes. Accordingly, we aimed to identify robust reference genes for normalization of gene expression in melanoma. The robustness of 24 candidate reference genes was evaluated across 80 formalin-fixed paraffin-embedded melanomas of different thickness, −/+ ulceration, −/+ reported cases of metastases and of different BRAF mutation status using quantitative real-time PCR. The expression of the same genes and their robustness as normalizers was furthermore evaluated across a number of melanoma cell lines. We show that housekeeping genes like GAPDH do not qualify as stand-alone normalizers of gene expression in melanoma. Instead, we have as the first identified a panel of robust reference genes for normalization of gene expression in melanoma tumors and cultured melanoma cells. We recommend using a geometric mean of the expression of CLTA, MRPL19 and ACTB for normalization of gene expression in melanomas and a geometric mean of the expression of CASC3 and RPS2 for normalization of gene expression in melanoma cell lines. Normalization, according to our recommendation will allow for quantitative validation of potential novel melanoma biomarkers by quantitative real-time PCR. Melanoma Res 30: 26–38 Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.

Melanoma Research 2020, 30:26–38

Keywords: biomarker, cell lines, formalin-fixed paraffin-embedded, gene expression, melanoma, normalization, qRT-PCR, reference genes

\textsuperscript{a}Department of Biomedicine, Aarhus University, Departments of \textsuperscript{b}Oncology and \textsuperscript{c}Pathology, Aarhus University Hospital, Aarhus N, Denmark

Correspondence to: Mette Madsen, PhD, Department of Biomedicine, Aarhus University, Wilhelm Meyers Alle 3, bldg. 1234, DK-8000 Aarhus C, Denmark

Tel: +45 2699 2137; fax: +45 8612 8804; e-mail: mette@biomed.au.dk

Received 22 January 2019 Accepted 28 August 2019

Introduction

Due to the aggressiveness and lethality of metastatic melanoma cancer [1], many research groups have attempted to identify and characterize novel melanoma biomarkers that can predict increased risk of metastasis at an early stage. Established melanoma biomarkers like Breslow thickness and ulceration unfortunately fail to detect all melanomas in risk of metastatic spread [2,3] resulting in metastatic relapse at later time points. Accordingly, novel and better melanoma markers are wanted.

Nowadays screening for novel biomarkers is frequently performed using advanced technologies like Next Generation Sequencing (NGS) or RNA sequencing (RNAseq). However, simpler PCR-based methods, like quantitative real-time PCR (qRT-PCR), are routinely chosen for validation of potential biomarkers identified by these more advanced technologies [4]. The rationale being the cost-benefit of the analysis and that PCR-based methods do not require bioinformatics contrary to NGS or RNAseq data analysis.

For gene expression analyses and relative quantification (RQ), qRT-PCR remains one of the most applied technologies. A consensus on good qRT-PCR practice has been established through extensive experience with the technique [5]. Reliable RQ of gene expression levels relies on suitable reference genes for normalization [6,7] and comparable RNA integrity between the samples under investigation [5,8].

The robustness of qRT-PCR reference genes did not receive much attention in the early days of qRT-PCR and ‘housekeeping’ genes like GAPDH were continuously used for normalization of gene expression despite lack of evidence of their the robustness [9,10]. Actually, more and more studies have established that ‘housekeeping’ genes are not always stably expressed across a cohort [6,11,12]. Follow-up studies have shown that false conclusions may have been made because unstable reference genes were applied for normalization of target gene expression levels [11,13,14]. Nevertheless, studies are still published today
where the stability and robustness of the reference genes used for normalization of target gene expression has not been properly validated, and traditional housekeeping genes are still applied as normalizers, despite the risk of introducing bias [15–17].

The vast majority of all biomarker studies are unsuccessful, often due to failure in reproduction of study results and in the ability to reach statistical significance [18–22]. A critical obstruction might be the lack of properly validated reference genes for normalization of target gene expression measured in the samples under investigation.

Aiming to pave the way for successful melanoma biomarker studies and for optimization of qRT-PCR-based analyses of gene expression in melanoma samples in general, we set out to identify and validate robust melanoma reference genes.

Methods
FFPE melanoma samples and melanoma cell lines
Melanoma FFPE tissue specimens were selected from the archives at the Department of Pathology, Aarhus University Hospital, Aarhus, Denmark. FFPE melanoma blocks established upon surgical resection of primary melanomas from 93 patients were included in this study. Of these 93 samples, 13 were used for the initial study of ACTB and GAPDH stability, whereas the other 80 samples were used for the main study of the stability of 24 selected reference gene candidates. From each melanoma block 3–6 sections of 10 µM were sliced. All sections were macro-dissected before RNA purification; the skin samples based on E-cadherin stainings of parallel sections and the melanoma samples based on E-cadherin and Melan A stainings of parallel sections. The study was approved by the local Ethical Committee (journal numbers; 48648 and 55836).

The human melanoma cell lines FM3 [European Searchable tumor line database (ESTDAB)-007], FM82 (ESTDAB-027), FM88 (ESTDAB-029) and FM92 (ESTDAB-032) were used in this study and were a kind gift from Professor Per Guldberg at The Danish Cancer Society [23,24]. Sub-clonal cell lines of the parental FM3 and FM88 cell lines were previously established [25], and the following cell lines were used in this study; 31-D3, 31-D8, 35-E1, 35-F1, 35-G7 of FM3 and 881-D9, 881-H6, 885-D3, 885-D10 of FM88. Cells were grown in RPMI 1640 (Life Technologies, Naerum, Denmark) supplemented with 10% heat-inactivated fetal bovine serum (BioWest, VWR, Herlev, Denmark), 100 U/ml penicillin and 100 µg/ml streptomycin, and 2 mM L-glutamine (BioWest, VWR, Herlev, Denmark), 100 µg/ml streptomycin, and 2 mM L-glutamine (BioWest, VWR, Herlev, Denmark) under normoxic condition at 37°C.

RNA extraction and cDNA synthesis
RNA was extracted from cell culture pellets and sections of paraffin-embedded tissue samples using the RNeasy Mini Kit and the RNeasy FFPE Kit (both Qiagen, Copenhagen, Denmark), respectively. An additional on-column DNase (Qiagen) digestion step was performed to remove genomic DNA. mRNA was converted into cDNA using the High-Capacity cDNA Reverse Transcription Kit on a Verity Thermal Cycler (both Applied Biosystems, Naerum, Denmark). gDNA background was evaluated in no reverse transcriptase control reactions.

RNA quality test by multiplex GAPDH Reverse Transcription-PCR
A multiplex reverse transcription-PCR (RT-PCR) was performed using the OneStep RT-PCR kit (Qiagen) on a Verity Thermal Cycler (Applied Biosystems) with the following GAPDH forward (FW) and reverse (R) primers in combination; hGAPDH_FW: 5′-CGA CAG TCA GCC GCA TCT T′3′ (h for human), hGAPDH_R1: 5′-CCC CAT GTG GTC TGA GCC GCG-3′, product size with FW-primer: 62 bp, hGAPDH_R2: 5′-AAG CAG CCC TGG TGA CGA G-3′, product size with FW-primer: 123 bp, hGAPDH_R3: 5′-GCC ATG GAA TTT GCC ATG GG-3′, product size with FW-primer: 230 bp, hGAPDH_R4: 5′-CCA GCA TCG CCC CAC TTG A-3′, product size with FW-primer: 328 bp. This cocktail of primer pairs for amplification of GAPDH RT-PCR products of varying lengths was used to evaluate the quality of RNA extracted from sections of FFPE blocks. SYBR safe DNA gel stain (Thermo Fisher Scientific, Hvidovre, Denmark) and Gel loading dye (BioNordika, Herlev, Denmark) was used to visualize RT-PCR products using a Fuji LAS-3000 Imaging System (Fujifilm Europe Scandinavia AB, Saltsjö-Boo, Sweden).

RNA integrity measurements
RNA integrity was measured for RNA extracted from the 80 FFPE melanoma samples of the main study cohort and from the 13 cell lines using the RNA 6000 Nano Kit and a 2100 Bioanalyzer (Agilent Technologies, Glostrup, Denmark) according to manufacturer’s instructions. Results were evaluated using the 2100 Expert software (Agilent Technologies). RNA Integrity Numbers (RIN values) are displayed in Table of Supplemental Digital Content 1, http://links.lww.com/MR/A190.

Selection of reference gene panel
Candidate reference genes for gene expression analysis were selected from papers available in the Pubmed database and extracted using the following keyword combinations: “PCR” AND “reference” AND “melanoma”, “genes”[Mesh] AND “melanoma”[Mesh] AND “reference”, “qPCR” AND “melanoma”[Mesh], and from
traditionally used reference genes such as ACTB, GAPDH and B2M. In addition, reference genes suggested using the RefGene Tool (GENEVESTIGATOR, NEBION/ETH Zurich, 2008) [26] based on the following sample selections/datasets; Neoplasms malignant melanoma of skin, Oncology Skin neoplasm melanoma-HS_AFFY-U133A and Oncology Skin neoplasm melanoma-HS_AFFY-U133PLUS_2 were included [27–34]. Further filtering of candidate reference genes was performed to ensure a minimum of genes with overlapping functions or from similar or associated pathways. Furthermore, genes were included only if high-quality TaqMan assays were available. The 24 selected genes are shown in Table 1.

qRT-PCR
Gene-specific TaqMan assays were purchased from Applied Biosystems. All assays were designed to give amplicons of less than 100 base pairs (bp). Assay IDs are included in Table 1. The following TaqMan assays were applied: Candidate reference genes: ACTB: Hs00106656_g1, B2M: Hs99999907_m1, CASC3: Hs0021226_m1, CLTA: Hs01125777_g1, EEF1A1: Hs00265885_g1, GAPDH: Hs02758991_g1, GUSB: Hs0093627_m1, HMBS: Hs00609296_g1, HPR1: Hs0280695_m1, IPO8: Hs00183533_m1, MARPL19: Hs01040121_m1, RBM23: Hs01016973_m1, POLR2A: Hs01108265_m1, PUM1: Hs00472881_m1, SAP130: Hs0368617_m1, TBP: Hs00472620_m1, TFRC: Hs00951083_m1, UBC: Hs01867132_s1, PEX16: Hs00191337_m1, ENGASE: Hs00232467_m1, RPS2: Hs01034573_g1, ZNF70: Hs01934521_s1. Target genes for reference gene validation experiment: ACTB: Hs01060665_g1, GAPDH: Hs02758991_g1, LRP1: Hs00233856_m1. All of the assays contained FAM-coupled probes. qRT-PCR was performed using Taqman Fast Advanced Master Mix (Applied Biosystems), and a Quantstudio 3 Fast Real-Time PCR cycler (Applied Biosystems) according to standard procedures. Contamination was evaluated by including no template control (NTC) reactions. Interplate variation was assessed by running an interplate control on a standard template for a study-unrelated target gene. All reactions were performed as technical triplicates. PCR efficiency were calculated based on standard curves by the equation: PCR efficiency = (10^{−1/slope} − 1) × 100. PCR reaction efficiencies for the recommended assays were between 99.53% and 106.65%.

Table 1: Overview of candidate reference genes included in the study

| Gene symbol | Gene name | Gene function | Assay ID* | Amplicon size (bp) |
|-------------|-----------|---------------|-----------|-------------------|
| ACTB        | Actin, β-Actin | Cytoskeletal protein | Hs01060665_g1 | 63 |
| B2M         | β2-microglobulin | Component of the MHC class I molecule | Hs99999907_m1 | 75 |
| CASC3       | Cancer susceptibility candidate 3 | Core component of the exon junction complex | Hs0021226_m1 | 67 |
| CLTA        | Clathrin light chain A | Component of coated pits and vesicles | Hs01125777_g1 | 71 |
| EEF1A1      | Eukaryotic translation elongation factor-1 alpha 1 | Subunit of the elongation factor-1 complex | Hs00265885_g1 | 75 |
| GAPDH       | Glyceraldehyde-3-phosphate dehydrogenase | Glycolysis | Hs02758991_g1 | 93 |
| GUSB        | β-Glucuronidase | Degradation of dermatan and keratan sulfates | Hs0093627_m1 | 96 |
| HMBS        | Hydroxymethylbilane synthase | Heme synthesis, porphyrin metabolism | Hs0089296_g1 | 69 |
| HPR1        | Hypoxanthine phosphoribosyl transferase | Purine salvage | Hs02800695_m1 | 82 |
| IPO8        | Importin 8 | Nuclear protein import | Hs0183533_m1 | 71 |
| MARPL19     | Mitochondrial ribosomal protein L19 | Component of the large ribosomal subunit | Hs01040217_m1 | 87 |
| RBM23       | RNA Binding Motif Protein 23 | RNA binding protein | Hs01016973_m1 | 58 |
| POLR2A      | RNA polymerase A | Catalyzes the RNA synthesis | Hs01108265_m1 | 71 |
| PPIA        | Peptidylprolyl isomerase A | cis-trans isomerization of proline imidic peptide bonds | Hs04194521_s1 | 97 |
| RPLF0       | Ribosomal protein, large, P0 | Structural protein of ribosomes | Hs02992885_s1 | 98 |
| PUM1        | Pumilio homolog 1 | Translational regulation of mRNA | Hs00472881_m1 | 77 |
| SAP130      | Sin3A-Associated Protein, 130kDa | Subunit of the SIN3A corepressor complex | Hs00988817_m1 | 76 |
| TBP         | TATA box binding protein | RNA polymerase II transcription factor | Hs00427620_m1 | 91 |
| TFRC        | Transferrin receptor | Uptake of iron | Hs00951083_m1 | 66 |
| UBC         | Ubiquitin C | Polyubiquitin precursor | Hs01867132_s1 | 82 |
| PEX16       | Peroxosomal Biogenesis Factor 16 | Integral peroxosomal membrane protein | Hs0191337_m1 | 75 |
| ENGASE      | Endo-Beta-N-Acetylglucosaminidase | Cytosolic enzyme | Hs0024267_m1 | 55 |
| RPS2        | Ribosomal Protein S2 | Component of the 40S ribosomal subunit | Hs01034573_g1 | 51 |
| ZNF70       | Zinc Finger Protein 70 | Regulation of gene expression | Hs01934521_s1 | 79 |

*Listed for each gene: TaqMan assay IDs and expected amplicon size.

Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
end-point PCR reaction (40 cycles) as the absolute quantification mode for the droplet reader. Contamination was evaluated by including NTC reactions. ddPCR data were analyzed using QuantaSoft Analysis Pro Software (BIORAD). The absolute quantity of target genes was normalized using the geometric mean of CASC3 and RPS2 quantities, and relative expression ratios between the 13 cell lines were calculated from the normalized absolute quantities.

RNA sequencing
Total RNA purified from two cell lines was sent for RNAseq at BGI Europe Genome Center (Copenhagen, Denmark). From total RNA samples, mRNA was purified using Oligo-(dT) magnetic beads. Purified mRNA was fragmented and reversely transcribed to cDNA using random hexamers and made double-stranded (ds). Adaptors were ligated to ends of ds cDNA, and ligation products were amplified by PCR using adaptor specific primers. Amplified PCR products were denatured and made cyclic by splint-oligos and DNA ligation. Before BGISEQ-500 library construction, RIN value, 28S/18S and the fragment length distribution and molar concentrations were analyzed using the RNA 6000 Nano Kit and a 2100 Bioanalyzer (Agilent Technologies) and evaluated in the 2100 Expert software (Agilent Technologies). Sequencing was performed on the BGISEQ-500 platform using single end sequencing strategy. Post sequencing low-quality reads, reads with adaptors and reads with unknown bases were filtered from the raw data to obtain clean data. Clean reads were mapped using HISAT algorithm to the Reference Genome Reference sequence and to the reference transcript using Bowtie2 software. RefSeq Assembly Accession matching GRCh38.p11 was applied as Reference Genome. Expression levels of genes were calculated by the FPKM method using the RSEM software package. FPKM data for the three selected target genes; LRPI, ACTB and GAPDH, were used for validation of CASC3 and RPS2 as reference genes by calculating the expression ratio for 31-D3 relative to 35-G7.

Data analysis
Initial evaluation of qRT-PCR analysis data was performed using the QuantStudio Design & Analysis Software v 1.4.1 (Applied Biosystems). Data are reported as mean ± SD. qRT-PCR was performed as far as possible according to MIQE guidelines [5]. Gene expression stability was evaluated for all 24 candidates using the geNorm [35] and NormFinder [36] algorithms as Excel add-ins.

The geNorm algorithm is based on the estimation of gene expression ratios, defined as stability measures. For each potential reference gene, the pairwise variation (V) to all the other evaluated genes is estimated as the SD of Log₂-transformed expression ratios. Finally, a gene stability measure (M) is estimated as the average pairwise variation for each gene. The M-value is thus used to evaluate the stability of the analyzed genes. The smaller the M-value, the more stably expressed is the reference gene. The determination of appropriate number of reference genes to include may be determined by evaluating the pairwise variation (V) on sequential addition to a normalization factor (NF).

The NormFinder algorithm is a model-based approach to estimating the variation in gene expression of candidate reference genes. The gene expression data is log-transformed and the intra- and inter-group variation estimated for the individual reference genes. The estimated intra- and inter-group variations are combined to form the NormFinder stability value, which directly describes the size of the systematic error added by each reference gene.

NormFinder has the advantage over geNorm in using subgroup estimates in the evaluation of reference gene stability. The final output for enabling calculation of the relative gene expression of target genes is a NF build from top-ranked genes estimated to introduce the least systematic error when applied as reference genes. The NF is calculated as the geometric average of the included reference genes. On an experimental basis, the number of reference genes to include is determined with regard to experimental design and by the acceptable level of variation. GraphPad Prism version 7 (GraphPad Software, Inc., La Jolla, California, USA) was used for graphic presentation of data and for correlation analysis of qRT-PCR and ddPCR data Pearson correlations were computed.

Results
Evaluation of the variation in ACTB and GAPDH expression levels amongst primary melanomas
The expression of ACTB and GAPDH in 13 primary melanomas was investigated by qRT-PCR. Multiple sections of each tumor were analyzed (minimum n = 3; maximum n = 6 per tumor), and inter- and intra-tumor variation in gene expression was evaluated to assess if ACTB and GAPDH could qualify as reference genes in qRT-PCR-based analysis of gene expression in melanoma tissue samples.

Across the 13 melanomas investigated here, gene expression varied 9.27 Cq values for ACTB and 8.41 Cq for GAPDH (ΔCq values). The inter-tumor variation is displayed in Fig. 1a and c.

Intra-tumor variation analysis was based on a minimum of three sections sampled with a two-section interval. The expression of ACTB varied between 0.16 Cq and 6.29 Cq, and GAPDH expression varied between 0.23 and 6.01 Cq within tumors. The intra-tumor variation is displayed in Fig. 1b and d.

RNA quality and the degree of RNA degradation in each sample was assessed by multiplex RT-PCR amplification of GAPDH fragments of variable length. Results
Fig. 1

ACTB and GAPDH mRNA expression variation in sections from 13 primary melanoma tumors. (a and c) Display the raw inter-tumor Cq variation and (b and d) display the raw intra-tumor Cq variation of ACTB and GAPDH, respectively. (e) Displays variable length of GAPDH fragments amplified by RT-PCR. Base pair (bp) markers of 100 bps and 200 bps are shown at the left. Bottom panels showing corresponding Cq values for ACTB and GAPDH in qRT-PCR. Cq, quantification cycle.
Robust reference genes for melanoma studies Christensen et al. 31

from GAPDH multiplex RT-PCR reactions for selected samples are shown in Fig. 1e. For tumors 1, 4, 5, 9, 10 and 12, the mRNA expression (Cq values measured by qRT-PCR) in all sections corresponded with the RNA quality assessed by GAPDH multiplex RT-PCR, where an increase in Cq value (decrease in expression) correlated with less amplification of the longer GAPDH fragments and vice versa. Intra-tumor GAPDH-specific Cq variation detected for these tumors may thus be caused by differences in RNA quality. This association between GAPDH mRNA expression and RNA quality was not observed for tumors 2, 3, 6, 8, 11 and 13. In some of the tumors with apparent high GAPDH mRNA expression as measured by qRT-PCR the RNA was actually vastly degraded. For example; in section 2.1, we measured high GAPDH mRNA expression (low Cq) by qRT-PCR compared to section 2.2 and 2.6, but the RNA quality for section 2.1 was poor compared to section 2.2 and 2.6. In section 3.4, we measured low GAPDH mRNA expression by qRT-PCR despite high quality of RNA measured by multiplex analysis. In section 11.3, we measured the highest expression of GAPDH mRNA (lowest Cq) by qRT-PCR; however the largest GAPDH fragment was not amplified from this section in multiplex RT-PCR indicating low RNA quality. Section 13.4 was the only section from tumor 13, from which we could amplify the largest GAPDH fragment; indicating higher RNA quality, however, amongst all the sections of tumor 13 the highest Cq (lowest GAPDH mRNA expression) was measured for section 13.4. Accordingly, we found no systematic association between the variation in gene expression levels (Cq values obtained by qRT-PCR) and the RNA quality (in terms of how long GAPDH fragments we could amplify in our multiplex RT-PCR).

To account for the contribution from cellular variations in the skin, for example, distribution of dermal cells and immunological infiltrates surrounding the tumor, to the variation in ACTB and GAPDH gene expression, we conducted RNA quality assessment by GAPDH multiplex RT-PCR and reference gene expression stability analyses by qRT-PCR using sections of non-cancerous cutaneous skin samples removed from five of the melanoma patients (1, 4, 7, 8 and 13). The measured expression of ACTB and GAPDH in the cutaneous samples varied up to 3.46 Cq and 3.47 Cq between samples, respectively (Fig. 2a and c). The intra-sample expression variation was between 0.07 and 1.92 Cq for ACTB and between 0.11 and 2.21 Cq for GAPDH (Fig. 2b and d). RNA isolated from the cutaneous samples from patients 1, 7 and 8 was of good quality and the reference gene expression corresponded well with the RNA quality (Fig. 2a, b and e). However, in section 4.1, higher mRNA quality was observed than for sections 4.4 and 4.7, but the GAPDH gene expression measured by qRT-PCR for sections 4.1, 4.4 and 4.7 was similar. Also, the GAPDH multiplex RT-PCR indicated low RNA quality in section 13.1, but qRT-PCR expression analysis resulted in Cq values of 32.7 for ACTB and 36.9 for GAPDH, which were substantially lower than for the corresponding section 13.4. It should also be noted that in general the average expression of ACTB and GAPDH the skin samples is fairly low compared to their expression in the melanoma samples. Accordingly, the contribution from the expression of these genes in normal skin is low compared to their expression in cancerous areas.

Identification of robust reference genes suitable for studies of gene expression in FFPE primary melanomas

Even though we macrodissected all skin and melanoma sections before RNA extraction and only included RNA samples with comparable RIN values, we observed a large degree of variation in gene expression levels of ACTB and GAPDH across the 13 melanoma samples investigated. We did not find any systematic association between the variation in gene expression and RNA quality. This disqualified the genes as stand-alone normalizers of gene expression in melanoma. According to Bustin et al. [5], normalization against a single reference gene is not acceptable unless it is invariantly expressed across all samples under investigation. We therefore initiated a study with the purpose of identifying a panel of the most robust and stably expressed reference genes in FFPE primary melanomas for use as normalizers of melanoma gene expression in qRT-PCR-based analyses.

We investigated the expression of these 24 candidate genes across 80 FFPE primary melanoma tumors selected across eight diagnostic subgroups. Figure 3 displays the grouping of patient samples included in this study. The qRT-PCR gene expression data were analyzed using geNorm and Normfinder algorithms to identify the most robust reference genes.

The geNorm algorithm identified the two genes; CLTA and RPS2, as the most stable genes across the 80 tumors (n = 80) (average stability value M = 0.500) (Fig. 4a) (also see output in Table of Supplemental Digital Content 2, http://links.lww.com/MR/A184). Thus, the optimal NF according to geNorm is calculated as the geometric mean of the reference genes CLTA and RPS2.

The NormFinder algorithm identified CLTA and MRPL19 as the optimal combination of reference genes when groups were taken into account (see data in Table of Supplemental Digital Content 3, http://links.lww.com/MR/A185). CLTA (stability value: 0.265) and MRPL19 (stability value: 0.268) were also identified as the most optimal reference genes (accumulated SD = 0.189), when grouping was not accounted for (Fig. 4b). By use of NormFinder, the optimal number of reference genes to include in order to reduce the technical variation to an accepted level, can be determined based on calculated accumulated SDs by sequentially adding candidate reference genes to the normalizer. From Fig. 4c, it
**Fig. 2**

**ACTB** and **GAPDH** expression variation in macro-dissected non-cancerous epidermal tissue samples. (a and c) Display the raw inter-tumor Cq variation and (b and d) display the raw intra-tumor Cq variation of **ACTB** and **GAPDH**, respectively. The epidermal sections were prepared from patient samples of a selected subgroup of patients in the cohort presented in Fig. 1 (corresponding numbers between melanomas/patients and cutaneous sections are shown below each diagram). (e) Displays variable length of **GAPDH** fragments detected by RT-PCR. Bp markers are shown at the left. Bottom panels show corresponding Cq values for **ACTB** and **GAPDH**. The epidermal sections are from a selected group of patients from Fig. 1 (corresponding numbers between tumors and cutaneous sections are shown). Cq, quantification cycle.
is evident that a substantial improvement of the CLTA/MRPL19 normalizer can be achieved by the inclusion of ACTB as an additional reference gene (accumulated SD = 0.156) (also see data in Table of Supplemental Digital Content 4, http://links.lww.com/MR/A186). Additional reference genes may be added to the CLTA/MRPL19/ACTB NF; however from the sixth included reference gene, the additional decrease in technical variation per added gene is minimal.

Identification of robust reference genes suitable for studies of gene expression in melanoma cell lines

We investigated the expression stability of ACTB and GAPDH across four melanoma cell lines; FM3, FM82, FM88 and FM92. ACTB and GAPDH expression (evaluated by ΔCq values ± standard error of the mean) varied 1.17 ± 0.05 and 1.21 ± 0.02 Cq, respectively (see output in Figure presented in Supplemental Digital Content 5, http://links.lww.com/MR/A189). The substantial variation in expression even when analyzing good quality starting material as fresh cell lysate enlightens that these two genes alone do not qualify as normalizers of target gene expression in qRT-PCR analyses in melanoma cell lines.

We then tested the expression of each of the 24 candidate reference genes across the four melanoma cell lines, as shown in Fig. 5a. The five most stably expressed genes across the four melanoma cell lines were CASC3 (0.51 ± 0.09), PUM1 (0.44 ± 0.23), HPRT1 (0.77 ± 0.10), POLR2A (1.14 ± 0.04) and RPS2 (0.85 ± 0.04), as can be seen in Fig. 5b. We proceeded by analyzing the expression of the five aforementioned genes along with ACTB and GAPDH to enable a comparison of commonly used reference genes and carefully selected reference genes, across nine additional melanoma cell lines. The difference in expression of the five genes can be seen in Fig. 5c. The two most stably expressed genes were CASC3 (0.87 ± 0.13) and RPS2 (0.89 ± 0.03). The panel of genes was further evaluated using the geNorm and NormFinder algorithms to establish the strongest panel of reference genes for use as normalizers of melanoma cell line gene expression data.

The geNorm algorithm identified the two genes CASC3 and RPS2 as the most robust reference genes across the tested melanoma cell lines (n = 13) (average stability value M = 0.380) (output in Fig. 5d; also see data in Table of Supplemental Digital Content 6, http://links.lww.com/MR/A187). In melanoma cell lines, a geometric mean of the reference genes CASC3 and RPS2 is estimated to be the most optimal NF according to geNorm.

The NormFinder algorithm supported these results as CASC3 (stability value: 0.102) and RPS2 (stability value: 0.214) were identified to be the best and second-best reference gene, respectively, across the tested melanoma cell lines (n = 13) (Fig. 5e) (also see data in Table of Supplemental Digital Content 7, http://links.lww.com/MR/A188). Subsequent grouping of the parental and sub-cloned cell lines further resulted in identification of CASC3 and RPS2 as the best combination of reference genes (FM82, FM92, FM88 and sub-clones, n = 7; FM3 and sub-clones, n = 6).

Thus, based on the results from the two algorithms the most optimal NF for melanoma cell lines can be calculated as a geometric mean of reference genes CASC3 and RPS2.

We compared our cell line results from the qRT-PCR-based analyses with corresponding data from other
technological platforms, specifically RNAseq and ddPCR, and validated the reliability of CASC3 and RPS2 as reference genes. In Fig. 5f, the expression ratios obtained by RNAseq for target genes LRP1, ACTB and GAPDH in the cell line 31-D3 relative to 35-G7 was compared with the RQ values obtained by qRT-PCR-based measurements. By pairwise comparison of the results for each target gene, it is evident that we obtain a pattern of similar expression ratios across these two different technological platforms. In Fig. 5g, we compared the normalized expression levels for the target gene LRP1 across 13 cell lines obtained by qRT-PCR-based measurements with the expression ratio obtained for the same target gene across the same 13 cell lines obtained by ddPCR. For both qRT-PCR- and ddPCR-based measurements, normalization of gene expression was conducted using CASC3 and RPS2 as reference genes. Very similar expression levels were obtained across the two different technological platforms, which is evident from an $R^2$ of 0.95. In Fig. 5h and I, we compared the normalized expression level for the target gene ACTB and GAPDH, respectively, across 13 cell lines obtained by qRT-PCR-based measurements with the expression ratios obtained for the same target gene across the same 13 cell lines obtained by ddPCR. Again very similar relative expression levels were obtained across the two different technological platforms for both ACTB and GAPDH indicated by an $R^2$ of 0.96 and 0.92, respectively.

CASC3 and RPS2 were also evaluated as reference genes in additional cancerous cell lines of melanocytic origin; WM115 and WM266-4, and in cell lines of non-melanocytic origin; HCC-70 (breast), and in BeWo, JEG-3 and JAR (of placental origin) (data not shown here), and even when these cell lines were included CASC3 and RPS2 were stably expressed across all samples investigated.

**Discussion**

In this study, we have analyzed the intra- and inter-tumor expression stability of the two commonly used reference genes, ACTB and GAPDH, in 13 FFPE melanoma samples by qRT-PCR. We show that the two genes are not stably expressed across the 13 melanomas investigated here and not even within individual melanoma tumors. The observed intra-and inter-tumor differences in expression of the two genes were not caused by dissimilar RNA integrities of samples compared but rather by a genuine fluctuation in expression levels.

We also examined the expression of ACTB and GAPDH in non-cancerous epidermal tissue samples taken from the melanoma patients, and we found that the expression of ACTB and GAPDH vary substantially between the normal epidermal tissue samples as well. This demonstrates that even for gene expression analyses in non-cancerous homogeneous skin samples, ACTB and GAPDH alone do not qualify as stand-alone normalizers of gene expression.
Fig. 5 (Continued)
We thus investigated the expression stability of 24 candidate reference genes in FFPE tissue samples collected from 80 melanoma patients. Patient samples from different diagnostic subgroups, counting tumors that were either BRAF mutated or not, tumors with or without ulceration, and thin as well as thick tumors were included. We applied two different mathematical algorithms for evaluation and comparison of the candidate reference genes. We identified *CLTA* as the most robust reference gene for normalization of gene expression in primary melanomas followed by *MRPL19* and *ACTB*, respectively.

However, the use of only a single reference gene for normalization of target gene expression data is not recommendable, especially not when analyzing tissue biopsies [37]. Instead, a multigene NF should be used, which is achieved by combining the expression of a number of validated genes [38]. The use of a multigene NF reduces the impact of fluctuations in a single reference gene resulting in higher quality results [38]. Based on our data, we recommend the use of a combined geometric mean of the expression levels of *CLTA*, *MRPL19* and *ACTB* for normalization of gene expression in FFPE melanomas. Inclusion of additional reference genes to this combined NF might improve it slightly, but as indicated in Fig. 4c, it will not decrease the variation substantially. Thus, with cost-benefits in mind we recommend a NF including these three genes (*CLTA*, *MRPL19* and *ACTB*) only. To our knowledge, our study is the first to systematically identify and validate a panel of robust reference genes for normalization of gene expression in primary melanomas.

For studies of gene expression in melanoma cell lines; we identified *CASC3* and *RPS2* as robust reference genes over 13 different melanoma cell lines. We recommend the use of a combined geometric mean of the expression levels of *CASC3* and *RPS2* for normalization of gene expression in melanoma cell lines.

We further compared gene expression data from different technical platforms. By comparing the relative expression ratios of target genes *LRP1*, *ACTB* and *GAPDH* across two melanoma cell lines estimated using an RNAseq approach and a qRT-PCR-based approach, we show that indeed we obtain similar relative gene expression levels of the target genes. We further compared the relative gene expression ratios of target genes *LRP1*, *ACTB* and *GAPDH* across 13 melanoma cell lines estimated by qRT-PCR or ddPCR. We find a strong correlation between data from qRT-PCR and ddPCR for each target gene demonstrating robustness of the reference genes *CASC3* and *RPS2* across technological platforms.

*CASC3* and *RPS2* also were evaluated as reference genes in yet two other melanoma cell lines and a number of other cell lines of origin different from melanoma (breast and placenta), and they were found to be robustly expressed in all cases. These two genes might therefore also qualify as normalizers of gene expression in cell lines of origin different from melanoma.

The discrepancy between the optimal reference genes identified for normalization of gene expression in FFPE melanomas and cultured melanoma cells and the different number of reference genes required to be included in the NF might be explained in two ways. First is the obvious difference in the quality of starting material. The integrity of the RNA is normally very high in fresh-frozen cell lysates, whereas the RNA integrity of FFPE tissue specimens is often very low [39,40]. Next, each investigated melanoma cell line is relatively homogenous, whereas melanoma tumors are highly heterogeneous entities [41–50].

In conclusion, this study has now established a panel of robust reference genes for use as normalizers in melanoma gene expression studies. This will hopefully pave the way for trustworthy, efficient and successful analyses of gene expression in primary melanomas regardless of
diagnostic subgroup and pave the way for validation of novel and better melanoma biomarkers.

Acknowledgements

We thank Dr. Marie Louise Bonnelkykke Behrndtz, Aarhus University Hospital for assistance in selection of melanoma samples and Sirem Egedal Degn and Thomas Wittemborn for assistance on ddPCR matters.

This study was supported by grants from Emil C. Hertz-, Georg Björkner-, Holm-, Einar Willumsen’s-, Frenkels- and Wedell-Erichsen’s foundations.

Conflicts of interest

There are no conflicts of interest.

References

1 Schadendorf D, Fisher DE, Garbe C, Gengerwald JE, Grob JJ, Halpem A, et al. Melanoma. Nat Rev Dis Primers 2015; 1:15003.
2 Balch CM, Gengerwald JE, Soong SJ, Thompson JP, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199–6206.
3 Garbe C, Eigentler TK, Bauer J, Blödorn-Schlicht N, Fend F, Hantschke M, et al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: review of the literature and recommendations for general practice. J Dtsch Dermatol Ges 2011; 9:690–699.
4 Field MG, Decatur CL, Kerntuchen SG, Geizgin G, van der Velden PA, Jager MJ, et al. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res 2016; 22:1234–1242.
5 Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55:611–622.
6 Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zulma A. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 2004; 37:112–114, 116, 118.
7 Derveaux S, Vandesompele J, Hellemans J. How to do successful gene expression analysis using real-time PCR. Methods 2010; 50:227–230.
8 Fleige S, Pfaffl MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med 2006; 27:125–139.
9 Sheils OM, Sweeney EC, TSH receptor status of thyroid neoplasms–TaqMan RT-PCR analysis of archival material. J Pathol 1999; 188:87–92.
10 Korbakis D, Gregorakis AK, Scorilas A. Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker. Clin Chem 2009; 55:904–913.
11 Glare EM, Devjak M, Bailey MJ, Walters EH. Beta-actin and GAPDH housekeeping gene expression in asthmatic airways is variable and not suitable for normalising mRNA levels. Thorax 2002; 57:785–770.
12 Suzuki T, Higgins PJ, Crawford DR. Control selection for RNA quantitation. Biotechniques 2000; 29:332–337.
13 Thellin O, Zorzi W, Lakaye B, De Borman B, Coomans B, Hennen G, et al. Housekeeping genes as internal standards: use and limits. J Biotechnol 1999; 75:291–295.
14 Dheda K, Huggett JF, Chang JS, Kim LU, Bustin SA, Johnson MA, et al. The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Anal Biochem 2005; 344:141–143.
15 Yao Z, Allen T, Oakley M, Samons C, Garrison D, Jansen B, et al. Analytical characteristics of a noninvasive gene expression assay for pigmented skin lesions. Assay Drug Dev Technol 2011; 14:385–383.
16 Gruselle O, Coche T, Louahed J. Development of a quantitative real-time RT-PCR assay for the detection of MAGE-A3-positive tumours. J Mol Diagn 2015; 17:382–391.
17 Gerami P, Yao Z, Polsky D, Boshen M, Busan K, Ho J, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol 2017; 76:114–120.e2.
18 McShane LM, Pileggi LM. Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility. Clin Trials 2013; 10:653–665.
19 Dougherty ER. Biomarker development: prudence, risk, and reproducibility. Bioessays 2012; 34:277–279.
20 Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, et al. Breaking a vicious cycle. Sci Transl Med 2013; 5:196cm6.
21 Poste G, Compton CC, Barker AD. The national biomarker development alliance: confronting the poor productivity of biomarker research and development. Expert Rev Mol Diagn 2015; 15:211–218.
22 Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol 2010; 28:698–704.
23 Jönsson G, Dahl C, Staaf J, Sandberg T, Bendahl PO, Ringnér M, et al. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 2007; 26:4738–4749.
24 Guldberg P, thor Straten P, Brink A, Ahrenkiel V, Kirstin AF, Zeuthen E. Disruption of the MMAC1/Pten gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997; 57:3660–3663.
25 Andersen RK, Hammer K, Hager H, Christensen NJ, Ludvigsen M, Honoré B, et al. Melanoma tumors frequently acquire LRP2/megalin expression, which modulates melanoma cell proliferation and survival rates. Pigment Cell Melanoma Res 2015; 28:267–280.
26 Hruz T, Wysm M, Docquier M, Pfaffl MW, Masanetz S, Borghi L, et al. Refgenes: identification of reliable and condition specific reference genes for RT-qPCR data normalization. BMC Genomics 2011; 12:158.
27 Hall A, Meyle KD, Lange MK, Klima S, Sanderhoff M, Dahl C, et al. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget 2013; 4:584–599.
28 Lebée C, Guedj M, Basset-Seguin N, Podgorniak MP, Menashi S, Janin A, Mourah S. A reliable method for the selection of exploitable melanoma archival paraffin embedded tissues for transcript biomarker profiling. Plos One 2012; 7:e29143.
29 Bonazzi VF, Irwin D, Hayward NK. Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes Chromosomes Cancer 2009; 48:10–21.
30 Jacob F, Guertler R, Naim S, Nixdorf S, Fedier A, Hacker NF, Heinzelmann-Schwarz V. Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and cancer cell lines. Plos One 2013; 8:e59180.
31 Cai J, Li T, Huang B, Cheng H, Ding H, Dong W, et al. The use of laser microdissection in the identification of suitable reference genes for normalisation of quantitative real-time PCR in human FFPE epithelial ovarian tissue samples. Plos One 2014; 9:e85974.
32 El Hajj P, Gilot D, Migault M, Theunis A, van Kempen LC, Salés F, et al. SNPs at mir-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma. Br J Cancer 2015; 113:91–98.
33 Zhan C, Zhang Y, Ma J, Wang L, Jiang W, Shi Y, Wang Q. Identification of reference genes for qRT-PCR in human lung squamous-cell carcinoma by RNA-seq. Acta Biochim Biophys Sin (Shanghai) 2014; 46:330–337.
34 Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010; 12:461–468.
35 Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. Reference relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007; 8:R19.
36 Andersen CL, Jensen JL, Omplot TF. Normalization of real-time quantitation reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004; 64:5245–5250.
37 Tricaricco C, Pinzani P, Bianchi S, Paglierani M, Distante V, Pazzagli M, et al. Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies. Anal Biochem 2002; 309:293–300.
38 Vandesompele J, De Preter K, Pattyn F, Poppe B, VanRoy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3:RESEARCH0034.
39 Stanta G, Schneider C. RNA extracted from paraffin-embedded human tissues is amenable to analysis by PCR amplification. Biotechniques 1991; 11:304, 306, 308.
40 Masuda N, Ohishi T, Kawamoto S, Monden M, Okubo K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res 1999; 27:4436–4443.
41 Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, et al. Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. Plos One 2012; 7:e59358.

Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
42 Heinzerling L, Baiter M, Kühnapfel S, Schuler G, Keikavoussi P, Agaimy A, et al. Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. Br J Cancer 2013; 109: 2833–2841.

43 Bradish JR, Richey JD, Post KM, Meehan K, Sen JD, Malek AJ, et al. Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy. Mod Pathol 2015; 28:480–486.

44 Valachis A, Ullenhag GJ. Discrepancy in BRAF status among patients with metastatic malignant melanoma: a meta-analysis. Eur J Cancer 2017; 81:106–115.

45 Hélias-Rodzewicz Z, Funck-Brentano E, Terrones N, Beauchet A, Zimmermann U, Marin C, et al. Variation of mutant allele frequency in NRAS Q61 mutated melanomas. BMC Dermatol 2017; 17:9.

46 Uguen A, Uguen M, Talagas M, Gobin E, Marcorelles P, De Braekeleer M. Fluorescence in situ hybridization testing of chromosomes 6, 8, 9 and 11 in melanocytic tumors is difficult to automate and reveals tumor heterogeneity in melanomas. Oncol Lett 2016; 12:2734–2741.

47 Harbst K, Lauss M, Girenajwis H, Isaksson K, Rosengren F, Törngren T, et al. Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma. Cancer Res 2016; 76:4765–4774.

48 Kågedal B, Farnebäck M, Håkansson A, Gustafsson B, Håkansson L. How useful are housekeeping genes? Variable expression in melanoma metastases. Clin Chem Lab Med 2007; 45:1481–1487.

49 Gerber T, Wilscher E, Leefler-Wirth H, Hopp L, Schadendorf D, Schartl M, et al. Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq. Oncotarget 2017; 8:846–862.

50 Zand S, Buzney E, Duncan LM, Dadras SS. Heterogeneity of metastatic melanoma: correlation of MITF with its transcriptional targets MLSN1, PEDF, HMB-45, and MART-1. Am J Clin Pathol 2018; 146:353–360.